286 related articles for article (PubMed ID: 6135795)
1. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
3. D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo.
Saller CF; Salama AI
J Pharmacol Exp Ther; 1986 Mar; 236(3):714-20. PubMed ID: 3005552
[TBL] [Abstract][Full Text] [Related]
4. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
Rosenzweig-Lipson S; Bergman J
J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
[TBL] [Abstract][Full Text] [Related]
6. Functional evidence for selective dopamine D-1 receptor blockade by SCH 23390.
Hyttel J
Neuropharmacology; 1984 Dec; 23(12A):1395-401. PubMed ID: 6152023
[TBL] [Abstract][Full Text] [Related]
7. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys.
Bergman J; Spealman RD; Madras BK; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 1996 Mar; 276(3):942-50. PubMed ID: 8786574
[TBL] [Abstract][Full Text] [Related]
8. Relative activities of SCH 23390 and its analogs in three tests for D1/DA1 dopamine receptor antagonism.
Barnett A; Ahn HS; Billard W; Gold EH; Kohli JD; Glock D; Goldberg LI
Eur J Pharmacol; 1986 Sep; 128(3):249-53. PubMed ID: 2878816
[TBL] [Abstract][Full Text] [Related]
9. Ergoline derivative LEK-8829-induced turning behavior in rats with unilateral striatal ibotenic acid lesions: interaction with bromocriptine.
Sprah L; Zivin M; Sket D
J Pharmacol Exp Ther; 1999 Mar; 288(3):1093-100. PubMed ID: 10027846
[TBL] [Abstract][Full Text] [Related]
10. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Park WK; Jeong D; Cho H; Lee SJ; Cha MY; Pae AN; Choi KI; Koh HY; Kong JY
Pharmacol Biochem Behav; 2005 Oct; 82(2):361-72. PubMed ID: 16216322
[TBL] [Abstract][Full Text] [Related]
11. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions.
Broening HW; Morford LL; Vorhees CV
Synapse; 2005 May; 56(2):84-93. PubMed ID: 15714503
[TBL] [Abstract][Full Text] [Related]
12. Identification of the binding subunit of the D1-dopamine receptor by photoaffinity crosslinking.
Amlaiky N; Berger JG; Chang W; McQuade RJ; Caron MG
Mol Pharmacol; 1987 Feb; 31(2):129-34. PubMed ID: 3807891
[TBL] [Abstract][Full Text] [Related]
13. Interaction of SCH 23390, a D-1-selective antagonist, with the anterior pituitary D-2 receptors and prolactin secretion in the rat.
Apud JA; Masotto C; Ongini E; Racagni G
Eur J Pharmacol; 1985 Jun; 112(2):187-93. PubMed ID: 2863153
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and dopamine receptor affinities of 6-amino-5,6,7,8-tetrahydroquinoline derivatives.
Claudi F; Cingolani GM; Giorgioni G; Cattabeni F; Cimino M; Di Luca M
Drug Des Deliv; 1989 Jun; 4(4):279-87. PubMed ID: 2570592
[TBL] [Abstract][Full Text] [Related]
15. Drug discrimination in methamphetamine-trained monkeys: agonist and antagonist effects of dopaminergic drugs.
Tidey JW; Bergman J
J Pharmacol Exp Ther; 1998 Jun; 285(3):1163-74. PubMed ID: 9618419
[TBL] [Abstract][Full Text] [Related]
16. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
17. (+/-)-3-[4'-(N,N-dimethylamino)cinnamyl]benzazepine analogs: novel dopamine D1 receptor antagonists.
Shah JH; Kline RH; Geter-Douglass B; Izenwasser S; Witkin JM; Newman AH
J Med Chem; 1996 Aug; 39(17):3423-8. PubMed ID: 8765528
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
[TBL] [Abstract][Full Text] [Related]
19. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
[TBL] [Abstract][Full Text] [Related]
20. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
